TRDA

TRDA is a pre-revenue, clinical-stage biopharma whose income statement is not investable on its own terms: FY2025 revenue fell 87.9% to $25.4M — and management is explicit that 'substantially all of our revenue to date has been derived from the Vertex Agreement,' i.e. lumpy collaboration payments, not product sales. Beneath that, the loss deepened sharply (net income -$144M vs. +$65.6M in FY2024, operating margin -621%, ROE -47%), R&D rose 13.5% to $142M, and operating cash burn hit -$129M. The FY2024 'profit' was an accounting artifact of collaboration timing, not a durable business — the five-year net-income history (-$51M, -$95M, -$7M, +$66M, -$144M) confirms there is no earnings trend to underwrite. On the standard biotech valuation lens the P/S of 11.6x is meaningless; the only figure that matters is cash.

And on that lens the setup is unusually clean: market cap of $296M sits almost exactly on the $295.7M of cash, cash equivalents and marketable securities management reports as of 12/31/25. The stock is priced at roughly net cash per share — the market is assigning near-zero value to the entire EEV pipeline. The balance sheet backs this up: liabilities/equity of just 0.23x, $306M equity, current assets of $306M against only $24.5M current liabilities. This is not a distressed balance sheet; it is a well-capitalized company the market has left for dead on pipeline skepticism, which is what makes it a hold rather than an avoid — there is a tangible downside cushion beneath a speculative option.